Next Article in Journal
Measuring Daylight: A Review of Dosimetry in Daylight Photodynamic Therapy
Previous Article in Journal
Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
Open AccessArticle

Tamoxifen Protects from Vesicular Stomatitis Virus Infection

1
Institute of Immunology, Medical Faculty, University of Duisburg-Essen, Hufelandstraße 55, Essen 45147, Germany
2
Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Hufelandstraße 55 45147 Essen, Germany
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Pharmaceuticals 2019, 12(4), 142; https://doi.org/10.3390/ph12040142
Received: 7 August 2019 / Revised: 30 August 2019 / Accepted: 17 September 2019 / Published: 20 September 2019
Background: Tamoxifen (TAM) is an estrogen-receptor antagonist, widely used in the adjuvant treatment of early stage estrogen-sensitive breast cancer. Several studies have revealed new biological targets of TAM that mediate the estrogen receptor independent activities of the drug. Recently, the antiviral activity of TAM on replication of human immunodeficiency virus (HIV), hepatitis C virus (HCV) and Herpes simplex virus (HSV-1) in vitro was described. In the current study, we aimed to investigate the effect of TAM on infection with vesicular stomatitis virus (VSV). Methods: Vero cells were treated with different concentrations of TAM for 24 h and then infected with VSV. Additionally, C57BL/6 mice were pretreated with 4 mg TAM, one day and three days before infection with VSV. Results: Treatment of Vero cells with TAM suppressed the viral replication of VSV in vitro and in vivo. The inhibitory effect of TAM on VSV replication correlated with an enhanced interferon-I response and stimulation of macrophages. Conclusions: TAM was identified as being capable to protect from VSV infection in vitro and in vivo. Consequently, this antiviral function (as an advantageous side-effect of TAM) might give rise to new clinical applications, such as treatment of resistant virus infections, or serve as an add-on to standard antiviral therapy. View Full-Text
Keywords: tamoxifen (TAM); vesicular stomatitis virus (VSV) infection; antiviral activity; interferon tamoxifen (TAM); vesicular stomatitis virus (VSV) infection; antiviral activity; interferon
Show Figures

Figure 1

MDPI and ACS Style

Cham, L.B.; Friedrich, S.-K.; Adomati, T.; Bhat, H.; Schiller, M.; Bergerhausen, M.; Hamdan, T.; Li, F.; Machlah, Y.M.; Ali, M.; Duhan, V.; Lang, K.S.; Friebus-Kardash, J.; Lang, J. Tamoxifen Protects from Vesicular Stomatitis Virus Infection. Pharmaceuticals 2019, 12, 142.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop